
News|Articles|April 15, 2014
- Pharmaceutical Technology-04-15-2014
- Volume 2014 eBook
- Issue 1
Using Modular Systems in Solid-Dosage Manufacturing
Author(s)Camilla Sivertsson
The authors describe how modular systems can be applied to continuous solid-dosage and nutraceutical manufacturing.
Advertisement
Modular systems offer a more efficient way to design and build manufacturing facilities. Although recent focus in the pharmaceutical industry has been on using modular systems in biopharmaceutical processing, the same advantages can be applied to small-molecule API and solid-dosage product manufacturing.
The authors describe how modular systems can be applied to continuous solid-dosage and nutraceutical manufacturing.
Download
.
Articles in this issue
over 12 years ago
Continuous Manufacturing for Solid-Dosage Drug Productionover 12 years ago
Advances in Hot-Melt Extrusion Manufacturingover 12 years ago
Selection of Excipients in Generic FormulationsAdvertisement
Related to this article

Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.

The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.

The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.

Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.

This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.

Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.

Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AI Formulation: Regulators Want Data
2
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
3
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
4
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
5


